Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 19 | 2019 | 466 | 2.660 |
Why?
|
| Airway Remodeling | 11 | 2017 | 19 | 2.290 |
Why?
|
| Tomography, X-Ray Computed | 23 | 2023 | 1641 | 1.680 |
Why?
|
| Lung | 8 | 2020 | 955 | 0.780 |
Why?
|
| Filariasis | 1 | 2022 | 23 | 0.750 |
Why?
|
| Forced Expiratory Volume | 8 | 2019 | 209 | 0.730 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 316 | 0.710 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2023 | 19 | 0.700 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2023 | 20 | 0.700 |
Why?
|
| Calcium | 2 | 2022 | 576 | 0.620 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 125 | 0.620 |
Why?
|
| Myocardium | 1 | 2021 | 279 | 0.610 |
Why?
|
| Vital Capacity | 4 | 2019 | 118 | 0.590 |
Why?
|
| Fistula | 1 | 2018 | 14 | 0.580 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 19 | 0.570 |
Why?
|
| Mitral Valve | 2 | 2021 | 125 | 0.560 |
Why?
|
| Calcinosis | 1 | 2018 | 86 | 0.540 |
Why?
|
| Lacrimal Apparatus | 2 | 2020 | 5 | 0.540 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 686 | 0.540 |
Why?
|
| Predictive Value of Tests | 10 | 2023 | 1092 | 0.530 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 92 | 0.530 |
Why?
|
| Bronchiectasis | 3 | 2019 | 13 | 0.480 |
Why?
|
| Severity of Illness Index | 9 | 2019 | 1553 | 0.470 |
Why?
|
| Neoplasms | 2 | 2022 | 1371 | 0.450 |
Why?
|
| Penile Neoplasms | 1 | 2014 | 1 | 0.440 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 208 | 0.440 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2017 | 695 | 0.430 |
Why?
|
| Penis | 1 | 2014 | 34 | 0.430 |
Why?
|
| Humans | 48 | 2024 | 63518 | 0.410 |
Why?
|
| Algorithms | 2 | 2020 | 1005 | 0.410 |
Why?
|
| Lymph Nodes | 1 | 2014 | 227 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 2184 | 0.390 |
Why?
|
| Image Enhancement | 1 | 2014 | 192 | 0.390 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 180 | 0.390 |
Why?
|
| Orbital Neoplasms | 1 | 2011 | 7 | 0.370 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2011 | 9 | 0.360 |
Why?
|
| Pulmonary Emphysema | 4 | 2016 | 108 | 0.340 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2024 | 107 | 0.340 |
Why?
|
| Phenotype | 8 | 2016 | 1207 | 0.330 |
Why?
|
| Eosinophilia | 4 | 2013 | 37 | 0.330 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 323 | 0.290 |
Why?
|
| Interleukin-5 | 3 | 2014 | 39 | 0.290 |
Why?
|
| Female | 28 | 2023 | 32939 | 0.290 |
Why?
|
| Bronchi | 3 | 2017 | 81 | 0.280 |
Why?
|
| Sputum | 5 | 2019 | 42 | 0.280 |
Why?
|
| Male | 26 | 2023 | 29928 | 0.280 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2022 | 67 | 0.270 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 175 | 0.270 |
Why?
|
| Adult | 16 | 2022 | 16891 | 0.260 |
Why?
|
| Ovary | 2 | 2022 | 102 | 0.240 |
Why?
|
| Middle Aged | 22 | 2023 | 17654 | 0.230 |
Why?
|
| Aged | 15 | 2023 | 14454 | 0.210 |
Why?
|
| Fibroblasts | 2 | 2016 | 394 | 0.210 |
Why?
|
| Cluster Analysis | 2 | 2015 | 262 | 0.200 |
Why?
|
| Computed Tomography Angiography | 2 | 2024 | 125 | 0.190 |
Why?
|
| Microfilariae | 1 | 2022 | 4 | 0.190 |
Why?
|
| Contrast Media | 2 | 2021 | 422 | 0.180 |
Why?
|
| Vascular Calcification | 1 | 2021 | 25 | 0.180 |
Why?
|
| Terminal Care | 1 | 2022 | 110 | 0.180 |
Why?
|
| Coronary Angiography | 1 | 2022 | 206 | 0.170 |
Why?
|
| Cardiology | 1 | 2023 | 168 | 0.170 |
Why?
|
| Orbital Pseudotumor | 1 | 2020 | 1 | 0.170 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2020 | 15 | 0.170 |
Why?
|
| Nephritis, Interstitial | 1 | 2020 | 15 | 0.170 |
Why?
|
| Fibrosis | 1 | 2021 | 160 | 0.170 |
Why?
|
| Biomarkers | 6 | 2016 | 1406 | 0.160 |
Why?
|
| Endovascular Procedures | 2 | 2024 | 600 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 97 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 51 | 0.160 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 113 | 0.160 |
Why?
|
| Consumer Behavior | 1 | 2019 | 38 | 0.160 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2021 | 119 | 0.150 |
Why?
|
| Orthopedics | 1 | 2019 | 33 | 0.150 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 11 | 0.150 |
Why?
|
| Aneurysm, Infected | 1 | 2019 | 13 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 117 | 0.150 |
Why?
|
| Aortography | 1 | 2019 | 57 | 0.150 |
Why?
|
| Curriculum | 1 | 2023 | 599 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1151 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 153 | 0.140 |
Why?
|
| Aneurysm, False | 1 | 2019 | 50 | 0.140 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2018 | 27 | 0.140 |
Why?
|
| Kidney | 1 | 2020 | 448 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 186 | 0.140 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2018 | 111 | 0.140 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2016 | 8 | 0.130 |
Why?
|
| Pediatrics | 1 | 2019 | 257 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 367 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6620 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 417 | 0.120 |
Why?
|
| Pregnancy | 1 | 2022 | 2335 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 604 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 117 | 0.110 |
Why?
|
| Bacteria | 1 | 2017 | 306 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 57 | 0.110 |
Why?
|
| Bronchography | 2 | 2011 | 5 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 237 | 0.110 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2014 | 10 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 92 | 0.110 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2014 | 61 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2015 | 606 | 0.100 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 54 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 518 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 1665 | 0.090 |
Why?
|
| Bronchial Diseases | 1 | 2012 | 13 | 0.090 |
Why?
|
| ROC Curve | 2 | 2011 | 282 | 0.090 |
Why?
|
| Actinomycosis | 1 | 2012 | 5 | 0.090 |
Why?
|
| After-Hours Care | 1 | 2012 | 9 | 0.090 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2012 | 9 | 0.090 |
Why?
|
| Animals | 3 | 2022 | 20691 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 177 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2012 | 32 | 0.090 |
Why?
|
| Angiography | 1 | 2012 | 151 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2019 | 1999 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 101 | 0.090 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2010 | 1 | 0.080 |
Why?
|
| Eosinophil Peroxidase | 1 | 2010 | 1 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 67 | 0.080 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 60 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 173 | 0.080 |
Why?
|
| Bronchitis | 1 | 2009 | 30 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 2584 | 0.070 |
Why?
|
| Observer Variation | 1 | 2009 | 215 | 0.070 |
Why?
|
| Time Factors | 1 | 2015 | 3706 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 56 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2012 | 724 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2024 | 5630 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 659 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 981 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 124 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2007 | 150 | 0.060 |
Why?
|
| Logistic Models | 1 | 2009 | 1267 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1234 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 863 | 0.050 |
Why?
|
| Macrophages | 1 | 2010 | 1041 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 350 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 805 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2024 | 76 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2016 | 663 | 0.050 |
Why?
|
| Mucins | 1 | 2003 | 27 | 0.050 |
Why?
|
| Respiratory Function Tests | 2 | 2016 | 190 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 20 | 0.050 |
Why?
|
| Adolescent | 3 | 2022 | 6258 | 0.050 |
Why?
|
| Aorta | 1 | 2024 | 110 | 0.050 |
Why?
|
| Breast Diseases | 1 | 2003 | 45 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2704 | 0.050 |
Why?
|
| Ontario | 1 | 2022 | 45 | 0.050 |
Why?
|
| United States | 3 | 2023 | 7837 | 0.050 |
Why?
|
| Amyloidosis | 1 | 2003 | 66 | 0.050 |
Why?
|
| Lymphoma | 1 | 2003 | 104 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2002 | 44 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 104 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1120 | 0.040 |
Why?
|
| Eosinophils | 2 | 2013 | 48 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5467 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2013 | 99 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2021 | 120 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 222 | 0.040 |
Why?
|
| Palliative Care | 1 | 2022 | 235 | 0.040 |
Why?
|
| Stents | 1 | 2024 | 489 | 0.040 |
Why?
|
| Meaningful Use | 1 | 2019 | 9 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 791 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 418 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 194 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 71 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2019 | 29 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 48 | 0.040 |
Why?
|
| Gadolinium | 1 | 2019 | 108 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 136 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 287 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 69 | 0.040 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2020 | 110 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2019 | 329 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 268 | 0.030 |
Why?
|
| Prevotella | 1 | 2017 | 2 | 0.030 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 188 | 0.030 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2017 | 10 | 0.030 |
Why?
|
| Streptococcus | 1 | 2017 | 18 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2017 | 32 | 0.030 |
Why?
|
| Young Adult | 2 | 2022 | 4712 | 0.030 |
Why?
|
| United Kingdom | 1 | 2017 | 80 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 88 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 133 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 267 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 196 | 0.030 |
Why?
|
| Software | 1 | 2019 | 388 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 408 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2016 | 1350 | 0.030 |
Why?
|
| Respiratory System | 1 | 2016 | 46 | 0.030 |
Why?
|
| Spirometry | 1 | 2016 | 112 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 197 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 267 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 361 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2019 | 274 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2014 | 3296 | 0.030 |
Why?
|
| Microbiota | 1 | 2017 | 129 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1386 | 0.030 |
Why?
|
| Inflammation | 2 | 2012 | 1146 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 931 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2027 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 234 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 1205 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 490 | 0.030 |
Why?
|
| Chemokine CCL11 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 455 | 0.020 |
Why?
|
| England | 1 | 2013 | 30 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 54 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2013 | 25 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2013 | 33 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 60 | 0.020 |
Why?
|
| Quality of Life | 2 | 2011 | 1241 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 456 | 0.020 |
Why?
|
| Actinomyces | 1 | 2012 | 3 | 0.020 |
Why?
|
| Forearm | 1 | 2012 | 22 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 130 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 62 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2012 | 89 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5284 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 106 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 265 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2011 | 18 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 61 | 0.020 |
Why?
|
| Mast Cells | 1 | 2011 | 39 | 0.020 |
Why?
|
| Neutrophils | 1 | 2013 | 376 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 662 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 868 | 0.020 |
Why?
|
| Child | 1 | 2019 | 4541 | 0.020 |
Why?
|
| Prednisolone | 1 | 2009 | 10 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2009 | 26 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 840 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 182 | 0.020 |
Why?
|
| Health Status | 1 | 2011 | 443 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2464 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 719 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 164 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 467 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 738 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1181 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 895 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1079 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 507 | 0.010 |
Why?
|
| Amyloid | 1 | 2003 | 70 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2003 | 126 | 0.010 |
Why?
|
| Hospitalization | 1 | 2009 | 1360 | 0.010 |
Why?
|
| Colon | 1 | 2002 | 149 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3031 | 0.010 |
Why?
|
| Mammography | 1 | 2003 | 290 | 0.010 |
Why?
|